ClinicalTrials.gg
Active, not recruitingNCT06495476GRACEUpdated Oct 8, 2026

Study on Ginkgo Biolba Extract Fifty and Mild Cognitive Impairment Associated With CSVD

A Phase 2/3 interventional study of Ginkgo biloba extract 50 dropping pills and Ginkgo biloba extract Ginkgo biloba extract 50 Drops simulant in Mild Cognitive Impairment, sponsored by Beijing Tiantan Hospital. Active, not recruiting at 1 site in China. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Beijing Tiantan Hospital · Phase 2/3, Interventional, and Treatment

How we know

Updated Oct 8, 2026Now Active, not recruitingFirst site in China+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
50 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Cognitive Dysfunction by Beijing Tiantan Hospital — 10 open to participants now, 11 under way, 1 of them phase 3. Cognitive Dysfunction · Beijing Tiantan Hospital.

Started
2024
with 5 others
Phase 2/3
Only one
of the 14
Primary completion
2026-10
later than 6 of 10 live
Registered
7th of 14
by date

Among the 14 studies in Cognitive Dysfunction by Beijing Tiantan Hospital, this one is one of 6 that started in 2024, is the only one in phase 2/3, reaches primary completion later than 6 of the 10 other live ones, and was the 7th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

10 of the 14 studies in Cognitive Dysfunction by Beijing Tiantan Hospital are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 50 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Cognitive Dysfunction by Beijing Tiantan Hospital, or all of them as a file.
02

Study summary

This study aimed to explore the efficacy and safety of Ginkgo Biolba Extract fifty in treating mild cognitive impairment associated with cerebral small vessel disease (CSVD). Subjects included based on eligibility criteria were randomized into treatment and control groups. Patients will receive the drug or placebo for 12 months. Patients were followed at baseline and at 3 months, 6 months, and 12 months after randomization. The primary outcome was the difference from baseline in the Montreal Cognitive Assessmen (MoCA) score at 12 months after randomization.

03

Conditions studied

  • Mild Cognitive Impairment
04

Who can participate

The criteria were revised on the registry on Oct 8, 2026. See what changed

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 50-75 years old, with no limitation on sex.
  2. Head MRI showed SVD lesions. High white matter signal, Fazekas score ≥2 and meet one of the following requirements:

    Have ≥2 vascular risk factors (hypertension, hyperlipidemia, diabetes, current smoking); Combined lacunar foci; Combined with a new subcortical lacunar infarction (within 7 days of onset);

  3. Mild vascular cognitive impairment (memory and/or other cognitive domain abnormalities lasting for at least 3 months) with a score of 18 ≤ score \< 26.
  4. Insufficient cognitive impairment to affect independence of life (mRS≤2).
  5. After enrollment, you can live in the local stable for more than two years.
  6. Sign the form.

Exclusion criteria

Exclusion Criteria:

  1. Known or suspected allergy to the components of the drug or allergic constitution.
  2. With other brain diseases: Alzheimer's disease, Lewy body dementia, Parkinson's disease frontotemporal dementia, Crohn's disease, as well as other diseases that can lead to cognitive impairment, such as subdural hematoma, communicating hydrocephalus, brain tumors, drug poisoning, alcoholism, thyroid disease, and vitamin deficiency.
  3. Previous diagnosis of genetic/degenerative/inflammatory related small cerebral vascular diseases, such as CADASIL, CARASIL, etc.
  4. Concomitant with major depressive disorder (≥24 score in HAMD-17) or other transient organic psychosis (e.g., schizophrenia) that meets criteria.
  5. Any medication used to treat cognitive impairment in the 4 weeks prior to randomization.
  6. Combined with severe neurological impairment, such as convenient hand hemiplegia, aphasia, auditory and visual impairment, the relevant examination or scale evaluation can not be completed.
  7. Combined with severe gastrointestinal diseases such as indigestion, gastrointestinal obstruction, gastric and duodenal ulcers that can affect drug absorption, or inability to swallow medication.
  8. Liver enzymes (, AST)>2 times the value, creatinine>1.2 times the upper limit of normal value, and decreased (\<60ml/min).
  9. \< 1 year, or other reasons for not being able to complete follow-up.
  10. Pregnant or lactating women, or those with fertility plans.
  11. Has participated in other clinical trials.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
144 participants (actual)

Study arms

  • Active comparator
    Ginkgo biloba extract 50 dropping pills treatment group

    Ginkgo biloba extract 50 dropping pills, oral administration, 8 dropping pills /time, 3 times/day

    Drug: Ginkgo biloba extract 50 dropping pills

  • Placebo comparator
    Ginkgo biloba extract 50 dropping pills Simulant treatment group

    Ginkgo biloba extract 50 dropping pills simulant, oral administration, 8 dropping pills /time, 3 times/day

    Drug: Ginkgo biloba extract Ginkgo biloba extract 50 Drops simulant

Interventions

  • DrugGinkgo biloba extract 50 dropping pills

    Composition: Ginkgo ketone ester, excipient polyethylene glycol 6000. Size: 10mg ginkgolides/pill.

  • DrugGinkgo biloba extract Ginkgo biloba extract 50 Drops simulant

    Composition: The main ingredient is polyethylene glycol 6000 + caramel pigment, placebo and ginkgolide drops are basically the same in color, odor and appearance. Size: 10 mg analog ingredient/pill.

06

What researchers measure

Primary outcomes

  1. Change from baseline in Montreal Cognitive Assessment Scale

    Montreal Cognitive Assessment Scale (Beijing Edition) scores from 0 to 30. A higher score indicates better cognitive function.

    Time frame: At 12months±14days after randomization.

Secondary outcomes

  1. Change from baseline in Montreal Cognitive Assessment Scale

    Montreal Cognitive Assessment Scale (Beijing Edition) scores from 0 to 30. Higher score indicates better cognitive function.

    Time frame: At 3months±7days and 6months±14days after randomization.

  2. Changes from baseline in total cerebral small vessel disease burden

    The severity of periventricular WMH (PV-WMH) and the deep-WMH were rated by Fazekas rating scale. The numbers of lacune and cerebral microbleed (CMB) will be collected. Perivascular spaces (PVS) in the basal ganglia was rated with the semi-quantitative rating scale developed by the Edinburg group. Total CSVD burden was the sum of points awarded for the presence or absence of four MRI markers: one point was awarded if lacunes were present, one point was awarded if CMBs were present, one point was awarded if there were moderate to severe PVS (\>10) in the basal ganglia, and one point was awarded for either confluent deep WMH (Fazekas scale 2 or 3) or irregular PV-WMH extending into the deep white matter (Fazekas score 3).

    Time frame: At 12months±14days after randomization.

  3. Changes from baseline in Mini-mental State Examination score

    Mini-mental State Examination (MMSE) scores from 0 to 30. A higher score indicates better cognitive function.

    Time frame: At 3months±7days, 6months±14days and 12months±14days after randomization.

  4. Change from baseline in the Ability Daily Living score

    Ability Daily Living (ADL) scores from 14 to 56. A higher score indicates a worse ability of daily living.

    Time frame: At 3months±7days, 6months±14days and 12months±14days after randomization.

  5. Change from baseline in Social functioning questionnaire

    Social functioning questionnaire (FAQ) scores from 0 to 30. A higher score indicates a worse capacity of action.

    Time frame: At 3months±7days, 6months±14days and 12months±14days after randomization.

  6. Change from baseline in biomarkers

    Biomarkers including hs-CRP, IL-6, TNF-α, Hcy, D-dimer, Fib

    Time frame: At 3months±7days, 6months±14days and 12months±14days after randomization.

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2024 (actual). Primary completion is estimated for Oct 2026, 25 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Dec 2025 → Oct 2026 and completion Jun 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2024
First posted
Jul 10, 2024
StartActual
Sep 27, 2024
Primary completionEst.
Oct 30, 2026was Dec 2025
CompletionEst.
Oct 30, 2026was Jun 2026
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Active, not recruiting
changed Oct 8, 2026
Sites
1 site added — first site in China
Show site
  • Beijing Tiantan Hospital, Capital Medical University · Beijing, China
Oct 8, 2026
Start date
Sep 1, 2024→Sep 27, 2024 (actual)
Oct 8, 2026
Primary completion
Dec 31, 2025→Oct 30, 2026
Oct 8, 2026
Study completion
Jun 30, 2026→Oct 30, 2026
Oct 8, 2026
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • EditedLiver enzymes (ALT, AST)>2 times the upper limit of normal value, creatinine>1.2 times the upper limit of normal value, and decreased glomerular filtration rate (<90ml60ml/min).
Oct 8, 2026
Design
Added Phase 2·Phase 3; removed Phase 4
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Not yet recruiting→Active, not recruiting
    1 site added — first site in China
    Show site
    • Beijing Tiantan Hospital, Capital Medical University · Beijing, China
    Start date Sep 1, 2024→Sep 27, 2024 (now actual)
    Primary completion Dec 31, 2025→Oct 30, 2026
    Study completion Jun 30, 2026→Oct 30, 2026
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • EditedLiver enzymes (ALT, AST)>2 times the upper limit of normal value, creatinine>1.2 times the upper limit of normal value, and decreased glomerular filtration rate (<90ml60ml/min).
    Design Added Phase 2·Phase 3; removed Phase 4
    + 3 other changes: verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06495476
Responsible party
yilong Wang (Vice President of Beijing Tiantan Hospital, Beijing Tiantan Hospital) — Principal investigator
First posted
Jul 10, 2024
Start date
Sep 27, 2024
Primary completion
Oct 30, 2026 (estimated)
Completion
Oct 30, 2026 (estimated)
Last update
Oct 8, 2026

Study contacts

Yuesong Pan
study director · Beijing Tiantan Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion